STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!